Related Experiment Video
Updated: Oct 28, 2025
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
5.5K
Glofitamab CD20-TCB bispecific antibody
Adrian Minson1,2, Michael Dickinson1,2
1Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia.
Leukemia & Lymphoma
|July 15, 2021
Summary
Glofitamab, a novel bispecific antibody, shows significant promise in treating B-cell lymphomas by targeting both T-cells and cancer cells. Clinical trials indicate high complete response rates, offering new hope for patients with limited treatment options.
Area of Science:
- Immunotherapy
- Oncology
- Hematology
Background:
- Bispecific T-cell recruiting antibodies are a potent immunotherapeutic class for B-cell malignancies.
- These antibodies engage T-cells and malignant cells to induce tumor cell death.
Purpose of the Study:
- To review the structure, mechanism of action, and pharmacokinetics of glofitamab.
- To present efficacy and safety data from ongoing clinical trials of glofitamab.
Main Methods:
- Review of available clinical trial data (Phase 1 monotherapy and combination).
- Overview of glofitamab's unique 2:1 configuration, full-length IgG-like CD20-CD3 bispecific structure.
- Analysis of pharmacokinetic properties and CD20 binding.
Main Results:
- >50% complete responses observed in heavily treated aggressive and indolent B-cell lymphoma patients at the recommended Phase 2 dose.
- Glofitamab demonstrates clear activity in monotherapy and combination settings.
- The 2:1 configuration provides extended half-life and superior CD20 binding.
Conclusions:
- Glofitamab is a promising addition to treatment options for B-cell lymphomas with limited therapeutic alternatives.
- Current data support evaluating glofitamab in combination therapies and earlier lines of treatment.
- Further research is warranted to fully establish its role in B-cell lymphoma management.
